Call Options

8 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$19.72 - $27.36 $222,836 - $309,168
11,300 Added 66.47%
28,300 $581,000
Q1 2024

May 14, 2024

SELL
$23.82 - $32.8 $214,380 - $295,200
-9,000 Reduced 34.62%
17,000 $467,000
Q4 2023

Feb 13, 2024

BUY
$23.16 - $32.34 $602,160 - $840,840
26,000 New
26,000 $792,000
Q1 2023

May 12, 2023

BUY
$33.3 - $44.82 $249,749 - $336,150
7,500 New
7,500 $279,000
Q2 2022

Aug 12, 2022

BUY
$38.49 - $76.21 $157,809 - $312,461
4,100 Added 21.35%
23,300 $1.21 Million
Q1 2022

May 13, 2022

BUY
$58.27 - $118.99 $1.12 Million - $2.28 Million
19,200 New
19,200 $1.4 Million
Q3 2021

Nov 12, 2021

SELL
$132.37 - $176.78 $2.71 Million - $3.62 Million
-20,500 Closed
0 $0
Q2 2021

Aug 13, 2021

BUY
$60.88 - $161.91 $1.25 Million - $3.32 Million
20,500 New
20,500 $3.32 Million

Others Institutions Holding NTLA

About Intellia Therapeutics, Inc.


  • Ticker NTLA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 76,011,800
  • Market Cap $1.06B
  • Description
  • Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemoph...
More about NTLA
Track This Portfolio

Track Peak6 Investments LLC Portfolio

Follow Peak6 Investments LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Peak6 Investments LLC, based on Form 13F filings with the SEC.

News

Stay updated on Peak6 Investments LLC with notifications on news.